Parkinson’s disease involves the malfunction and death of vital nerve cells in the brain called neuron which produce dopamine, a chemical that sends message to the part of the brain that controls movement and coordination. As Parkinson’s disease progresses, the amount of dopamine produced in the brain decreases, leaving a person unable to control movement normally. The test drug Ginkgolide B and standard drug Levodopa have targeted the protein D2 receptor (PDB ID: 2YOU) and protein D3 receptor (PDB ID: 3PBL) respectively. Both the test and standard drug were drawn using Chemsketch draw software and structures were optimized using Arguslab software. Then they were docked with the Dopamine D2 protein (PDB ID: 2YOU) and Dopamine D3 protein (PDB ID: 3PBL) using HEX software. The test drug showed improvement in binding affinity and other properties in comparison to standard drug.